DIRECTING PHARMACEUTICAL POLYMORPHISM THROUGH MAGNETISM

The MagnaPharm project initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields, having a transformative effect on almost all pharmaceutical compounds, and hence on society. 

 

 MagnaPharm is a collaborative research project funded by the European Union’s Horizon 2020 Research and Innovation programme under grant agreement number 736899. 

The MagnaPharm Consortium

The MagnaPharm Consortium - Lead by Dr Simon Hall, University of Bristol (centre)